Velpatasvir

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Velpatasvir (GS-5816) 是第二代 HCV NS5A 泛基因型抑制剂，在 HCV 复制子检测中表现出较高的耐药屏障。

Velpatasvir (GS-5816) is a second generation, pan-genotypic inhibitor of HCV NS5A, demonstrates a high barrier to resistance in HCV replicon assays.HCV Infection Phase 3 Clinical.

——

Animal Model:CCl4-induced non-HCV rat model Dosage:10 mg/kg/d alone, or in combination with Sofosbuvir (20 mg/kg/d) Administration:p.o.Result:Decreased the levels of TNF-a, NF-κB and IL-6 in serum and hepatic tissues.Inhibited hepatic stellate cells (HSCs).

GS-5816 | GS 5816 | GS5816

Microbiology/Virology

HCV

HCVNS5A

Infection

HCV Infection

1377049-84-7

883.0018

C49H54N8O8

>98% (HPLC)

DMSO: 146.66 mg/mL (Need ultrasonic and warming)

O=C(OC)N[C@H](C1=CC=CC=C1)C(N2[C@H](C3=NC=C(C4=CC5=C(C6=CC7=CC=C8C(NC([C@H]9N(C([C@H](C(C)C)NC(OC)=O)=O)[C@@H](C)CC9)=N8)=C7C=C6OC5)C=C4)N3)C[C@H](COC)C2)=O

Carbamic acid, N-[(1R)-2-[(2S,4S)-2-[5-[1,11-dihydro-2-[(2S,5S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-5-methyl-2-pyrrolidinyl][2]benzopyrano[4',3':6,7]naphth[1,2-d]imidazol-9-yl]-1H-imidazol-2-yl]-4-(methoxymethyl)-1-pyrrolidinyl]-2-oxo-

(-20℃)

With Ice Pack

≥ 2 years